Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin

Cancer

Volumn 86, Issue 8, 1999, Pages 1463-1469

  Feliu, Jaime ^a   Gómez, Luis López ^b   Madroñal, Caterina ^c   Espinosa, Enrique ^a   Espinosa, Javier ^d   Girón, Carlos García ^e   Martinez, Beatriz ^b   Castro, Javier ^a   De La Gándara, Isabel ^c   Barón, Manuel González ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Clínca Rúber   (Spain)

^e Medical Oncology Service   (Spain)

Author keywords

Comorbidity; Elderly; Gemcitabine; Nonsmall cell lung carcinoma; Toxicity; Vinorelbine

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; AGING; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; NEUTROPENIA; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; NEUTROPENIA; PERIPHERAL NERVOUS SYSTEM DISEASES; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINBLASTINE;

EID: 0344980098     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991015)86:8<1463::AID-CNCR12>3.0.CO;2-N     Document Type: Article

References (39)

1. Vercelli M, Quaglia A, Casella C, Parodi S, Micheli A, Capocaccia R. Cancer in elderly: the population-based indexes in Europe (incidence, mortality, survival and prevalence). Ann Oncol 1998;9(Suppl 3):55-6.
2. Yancik R. Cancer burden in the aged. An epidemiologic and demographic overview. Cancer 1997;80:1273-83.
3. Lee-Chiong TL Jr., Matthay RA. Lung cancer in the elderly patient. Clin Chest Med 1993;14:453-78.
4. Levi F, LaVecchia C, Lucchini F, Negri E. Worldwide trends in cancer mortality in the elderly, 1955-1992. Eur J Cancer 1996;32A:652-72.
5. de Rijke JM, Schouten LJ, Schouten HC, Jager JJ, Koppejan AG, van den Brandt PA. Age specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. Ann Oncol 1996;7:677-85.
6. Smith TJ, Penberthy L, Desch CE, Whittemore M, Newschaffer C, Hillner BE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 1995;13:235-52.
7. Balducci L, Extermann M. Cancer chemotherapy in the older patient. What the Medical Oncologist needs to know. Cancer 1997;80:1317-22.
8. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
9. Gridelli C, Perrone F, Gallo C, De Marinis F, Ianniello G, Cigolari S, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase 11 study. Eur J Cancer 1997;33:392-7.
10. Shepherd FA, Abratt RP, Anderson H, Gatzemeier U, Anglin G, Iglesias J. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 1997;24(Suppl 7):50-5.
11. Veronesi A, Crivellari D, Magri MD, Cartei G, Mansutti M, Foladore S, et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 1996;32:1809-11.
12. Martin C, Ardizzoni A, Rosso R. Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging Clin Exp Res 1997;9:297-303.
13. Kanzawa F, Saijo N. In vitro between Gemcitabine and other anticancer drugs using novel three-dimensional model. Semin Oncol 1997;24 (Suppl 7):8-16.
14. International Union Against Cancer. TNM atlas. Illustrated guide to the TNM/pTNM classification of malignant tumors. Berlin: Springer-Verlag, 1997.
15. Charlson ME, Pompei P, Ales KL, MacKenzie R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;42:207-14.
17. Hollen PJ, Gralla RJ, Kris M, Potanovich LM. Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS). Eur J Cancer 1993;29A (Suppl 1):51-8.
18. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-26.
20. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 1995; 13:1221-30.
21. Bizette GA, Gralla RJ, Rittenberg CN. Does older age or ethnic group influence survival or response in patients in clinical trials for non-small cell lung cancer (NSCLC)? Proc Am Soc Clin Oncol 1995;14:A333.
22. Rinaldi M, de Marinis F, Ardizzoni A, Pernucci MC, Bruzzi P, Salvati F, et al. Correlation between age and prognosis in patients with advanced non small cell lung cancer prognosis with cisplatin containing chemotherapy: a retrospective multicenter study. Ann Oncol 1994;5 (Suppl 8): 58.
23. Hickish TF, Smith IE, Ashley S, Middleton G. Chemotherapy for elderly patients with lung cancer. Lancet 1995;346: 580.
24. Kubota K, Furuse K, Kawahara M, Kodama N, Ogawara M, Takada M, et al. Cisplatin-based combination chemotherapy for elderly patients with non-small cell lung cancer. Cancer Chemother Pharmacol 1997;40:469-74.
25. Baldini E, Tibaldi E, Pfanner E, Ricci E, Falcone A, Ceribelli A, et al. Phase II of oral doxifluridine in elderly patients with advanced non small cell lung cancer. Am J Clin Oncol 1996; 19:592-4.
26. Furuse K, Fukuoka M, Hara N, Kurita Y, Kinuwaki E, Kawahara M, et al. Vinorelbine in the treatment of elderly patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998;17:A1862.
27. Gallotti P, Chiesa E, Olgiati A, Bottaro G, Natale G, Freddi E. Vindesine as monochemotherapy in non small cell lung cancer in elderly patients. Ann Oncol 1992;3 (Suppl 5):36.
28. Portalone L, D'Aprile M, De Marinis F, et al. Management of chemotherapy in elderly patients with advanced non small lung cancer (NSCLC)- a phase III randomized trial. Lung Cancer 1994;11 (Suppl 1):110.
29. Salvati F, Antilli A, Cruciani AR, Lombardi A, Muguaini L, Nunziati F, et al. Lonidamine plus cyclophosphamide in the treatment of advanced non small cell lung cancer in the elderly: a phase II study. Tumor 1995;81:48-51.
30. Gridelli C, Rossi A, Scognamiglio F, Guida C, Fiore F, Gatani T, et al. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study. Anticancer Res 1997;17:4755-8.
31. Malarme M, Marcelis L, Kaius JP, Brenez D, Feremans W, Bracops CHJ. Ifosfamide and vindesine therapy for non small lung cancer in the elderly. Ann Oncol 1992;3(Suppl 5):36.
32. Thyss A, Saudes L, Otto J, Creison A, Gaspard MH, Dassonville O, et al. Renal tolerance to cisplatin in patients more than 80 years old. J Clin Oncol 1994;12:2121-5.
33. Lippe P, Silva RR, Giuliodori L, Santo A, Cancellieri MA, Monterubbianesi MC, et al. Advanced non-small cell lung cancer in the elderly: effective and well tolerated weekly gemcitabine and cisplatin regimen. Ann Oncol 1998;9(Suppl 3):64.
34. Tononi A, Panzini I, Olivero G, Pasquini E, Gianni L, Nicolini M, et al. Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients. J Chemother 1997;9: 304-8.
35. Perrone F, Rossi A, Iannello GP, Maiorino L, Piantedosi FV, Cigolari S, et al. Vinorelbine plus best supportive care vs best supportive care in the treatment of advanced non-small cell lung cancer elderly patients. Results of a phase III randomized trial. Proc Am Soc Clin Oncol 1998;17:A1752.
36. Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. A meta-analysis of response, toxicity, and survival. Cancer 1998;82:116-26.
37. Yancik R, Wesley MN, Ries LAG, Havlik RJ, Long S, Edwards BK, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients. A population-based study. Cancer 1998;82:2123-34.
38. Lorusso V, Mancarella S, Carpagno F, Di Rienzo G, Cisterino L, Napoli G, et al. Gemcitabine plus vinorelbine in patients with stage IIIB-IV non small cell lung cancer. A phase II study. Proc Am Soc Clin Oncol 1998;17:A1808.
39. Esteban E, Llano JLG, Vieitez JM, Fra J, Puertas J, Estrada E, et al. Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Proc Am Soc Clin Oncol 1998;17: A1855.